Notice: Passwords are now case-sensitive

Remember Me
Register a new account
Forgot your password?

Purdue Developing Opioid Antagonist of Potential Interest to Comp

Friday, July 30, 2021 | 0

Purdue Pharma is developing a long-acting opioid antagonist for treating overdoses that will likely be of interest to the workers’ compensation community, pharmacy benefit manager myMatrixx reports. The drug under development, nalmefene, has a plasma half-life of almost 11 hours, myMatrixx said. The only FDA-approved treatment for opioid overdose, naloxone, has a half-life of about two hours. “As a result, nalmefene has been shown to reverse opioid intoxication for as long as eight hours, whereas naloxone requires monitoring and repeat dosing, as needed,” myMatrixx said. P...

Purchase this story for only $7.99!

For access to all of our articles, check out our subscription options.


Related Articles